From Data Aggregation to Improved Financial & Clinical Outcomes... What is possible now?
Scott Pryde BravoSolution UK
ŠALL RIGHTS RESERVED - Confidential
1
Alignment, Governance & Information
# Field Safety Notices
ŠALL RIGHTS RESERVED - Confidential
2
Reimbursement, Cost & Revenue Leakage
ŠALL RIGHTS RESERVED - Confidential
3
Underpinning Savings Initiatives
ŠALL RIGHTS RESERVED - Confidential
4
Hospital Spend Data Quality
NB One exception: Typically where there is a significant peak in Building and Construction works, the data quality drops to very low in that category as data on major works is almost always held on a separate construction system
ŠALL RIGHTS RESERVED - Confidential
5
Misleading Data
©ALL RIGHTS RESERVED - Confidential
6
MPN Overlap & Variety by Trust
% Overlap
% Common SKU by No. Of Trusts
# of Organisations ŠALL RIGHTS RESERVED - Confidential
7
What’s in a number ?
(Asset Identifier)(Organisation ID )(ProductCode)(Lot No.) XX(Serial No.)XXX
[C1 (8004) 12345699999 157004070 (19) 9999999 (21) 99999999
What’s not ? Catalogue Ref: 157004070 - C-STEM AMT SIZE1 STD OFFSET - EACH eClass:
Medical Prosthesis – Joint Replacement Hips
Benchmark:
Medical Devices - Orthopaedic – Primary – Hip - Stem – Uncemented
©ALL RIGHTS RESERVED - Confidential
8
Aggregation & Classification
ŠALL RIGHTS RESERVED - Confidential
9
Price Benchmarking
ŠALL RIGHTS RESERVED - Confidential
10
Evidence Tracking
ŠALL RIGHTS RESERVED - Confidential
11
Other Medical category examples ...
Trauma Nail Demand Volatility / Time
ŠALL RIGHTS RESERVED - Confidential
12
Opportunity Analysis & Guidance
©ALL RIGHTS RESERVED - Confidential
Spend
£557,160
% Savings
Value
Complexity
A
57%
£320,000
10
B
52%
£291,000
9
C D E F
27% 17% 13% -18%
£150,000 £96,000 £70,000 -£100,000
6 3 1 0
Aggressive brand repositioning to lower price high evidence cemented products e.g. Lubinus SPII, National Regional collaborative bulk commitment and surgeon led negotiation, Manage Consignments directly Alignment with National lowest price clinical policy and brand usage, Significant shift from uncemented to cemented products. Cllaborative, surgeon led negotiation and bulk commitment to maximise leverage Alignment with National average price aligning with technology indicator averages and brand choices. Collaborative, surgeon led negotiation and bulk commitment to maximise leverage Consolidate current brand usage and surgeon led commercial negotiation Ceramic on Ceramic - reduce to national average. Uncontroled brand usage & supply base fragmentation
13
Shared Market Intelligence
ŠALL RIGHTS RESERVED - Confidential
14
Summary
• Investing in data aggregation is essential alongside improving systems & standards • Data aggregation, analysis & information sharing is possible now • Improved financial and clinical outcomes will follow • BUT ..... information is a compass not a silver bullet ... delivery competency will still be required to achieve value • Co-operate to share market, technology , strategy expertise & knowledge across the system
©ALL RIGHTS RESERVED - Confidential
15
Executive Briefings
Hospital Benchmarking & Analytics Understanding GS1 & Data Aggregation Outcome led Contract Management MedTech Market Analysis Inventory, Demand & Utilisation Analytics Clinical Commissioning Group Spend Analysis CCG Non-Medical Auctions & Strategies
Scott Pryde BravoSolution UK
ŠALL RIGHTS RESERVED - Confidential
16